MediWound Ltd.
NASDAQ:MDWDBiotechnology
-$0.09 today
- Market cap
- $176.61M
- Beta
- 0.15
- P/E (TTM)
- -7.0
- EPS (TTM)
- -$2.03
Volume 0.16M
Average 0.09M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
MediWound Ltd.
NASDAQ:MDWD
Intrinsic Alpha fair value
Locked
Current Price
$13.68
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -13.8% | +59.0% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at -13.8% over three years. Forward estimates point to Revenue at +59.0% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
SELLAS Life Sciences Group, Inc. NASDAQ:SLS | $1.59B | $7.86 | Not rated | -47.3 | +1104.40% |
Eupraxia Pharmaceuticals Inc. NASDAQ:EPRX | $548.02M | $8.15 | Not rated | -8.5 | +3.92% |
Orchestra BioMed Holdings, Inc. NASDAQ:OBIO | $435.76M | $7.25 | Not rated | -2.8 | +64.78% |
Cartesian Therapeutics, Inc. NASDAQ:RNAC | $193.69M | $6.35 | Not rated | -1.7 | -19.69% |
Inventiva S.A. NASDAQ:IVA | $191.29M | $3.68 | Not rated | -5.5 | -22.97% |
Invivyd, Inc. NASDAQ:IVVD | $171.58M | $0.58 | Not rated | -3.9 | -79.74% |
Protara Therapeutics, Inc. NASDAQ:TARA | $155.77M | $2.53 | Not rated | -2.7 | -65.63% |
Neonc Technologies Holdings, Inc. NASDAQ:NTHI | $141.66M | $4.91 | Not rated | -3.0 | -38.67% |
Aardvark Therapeutics, Inc. Common Stock NASDAQ:AARD | $29.11M | $1.33 | Not rated | -1.2 | -59.86% |
Continue the stock analysis
Jump to another research area for this company.